What is Epistem?
Epistem operates as a specialized service provider at the intersection of biotechnology and clinical research. The firm provides a robust suite of preclinical and clinical services, specifically targeting high-stakes therapeutic areas such as oncology, inflammatory diseases, and gastrointestinal conditions. With a client base exceeding 200 pharmaceutical and biotechnology organizations, Epistem leverages its GCLP-accredited laboratories to deliver high-fidelity data in histology, gene expression, and DNA genotyping. Their business model is predicated on providing reliable, innovative platforms that facilitate informed decision-making throughout the drug development lifecycle, ensuring that custom protocols meet the rigorous demands of modern medical research.
How much funding has Epistem raised?
Epistem has raised a total of $9.5M across 1 funding round:
Private Equity
$9.5M
Private Equity (2016): $9.5M, investors not publicly disclosed
Key Investors in Epistem
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Epistem?
With the recent influx of capital, Epistem is well-positioned to scale its technical infrastructure and expand its service offerings. The company's strategic trajectory suggests a focus on deepening its expertise in personalized medicine and high-throughput diagnostic services. As the pharmaceutical industry continues to prioritize efficiency in early-stage development, Epistem's ability to provide scalable, GCLP-compliant research solutions will likely serve as a primary growth driver. Future initiatives will likely involve the integration of advanced analytical technologies to further refine their preclinical models, thereby maintaining their competitive edge in supporting the next generation of therapeutic breakthroughs.
See full Epistem company page
